FI113175B - Menetelmä terapeuttisesti käyttökelpoisten itrakonatsoli- ja saperkonatsoli-cis-stereoisomeerien valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten itrakonatsoli- ja saperkonatsoli-cis-stereoisomeerien valmistamiseksi Download PDF

Info

Publication number
FI113175B
FI113175B FI944311A FI944311A FI113175B FI 113175 B FI113175 B FI 113175B FI 944311 A FI944311 A FI 944311A FI 944311 A FI944311 A FI 944311A FI 113175 B FI113175 B FI 113175B
Authority
FI
Finland
Prior art keywords
phenyl
triazol
cis
ylmethyl
piperazinyl
Prior art date
Application number
FI944311A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI944311L (fi
FI944311A0 (fi
Inventor
Jan Heeres
Jean Louis Mesens
Jozef Peeters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25316567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI113175(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI944311L publication Critical patent/FI944311L/fi
Publication of FI944311A0 publication Critical patent/FI944311A0/fi
Application granted granted Critical
Publication of FI113175B publication Critical patent/FI113175B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
FI944311A 1992-03-18 1994-09-16 Menetelmä terapeuttisesti käyttökelpoisten itrakonatsoli- ja saperkonatsoli-cis-stereoisomeerien valmistamiseksi FI113175B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85364892A 1992-03-18 1992-03-18
US85364892 1992-03-18
EP9300552 1993-03-10
PCT/EP1993/000552 WO1993019061A1 (en) 1992-03-18 1993-03-10 Itraconazole and saperconazole stereoisomers

Publications (3)

Publication Number Publication Date
FI944311L FI944311L (fi) 1994-09-16
FI944311A0 FI944311A0 (fi) 1994-09-16
FI113175B true FI113175B (fi) 2004-03-15

Family

ID=25316567

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944311A FI113175B (fi) 1992-03-18 1994-09-16 Menetelmä terapeuttisesti käyttökelpoisten itrakonatsoli- ja saperkonatsoli-cis-stereoisomeerien valmistamiseksi

Country Status (21)

Country Link
US (1) US5998413A (cs)
EP (1) EP0631578B1 (cs)
KR (1) KR100243534B1 (cs)
AT (1) ATE201408T1 (cs)
AU (1) AU665988B2 (cs)
CA (1) CA2117651C (cs)
CZ (1) CZ286619B6 (cs)
DE (1) DE69330248T2 (cs)
DK (1) DK0631578T3 (cs)
ES (1) ES2158859T3 (cs)
FI (1) FI113175B (cs)
GR (1) GR3036368T3 (cs)
HU (1) HU221189B1 (cs)
NO (1) NO307786B1 (cs)
NZ (1) NZ249494A (cs)
PL (1) PL172358B1 (cs)
PT (1) PT631578E (cs)
RU (1) RU2127733C1 (cs)
SK (1) SK283118B6 (cs)
WO (1) WO1993019061A1 (cs)
ZA (1) ZA931906B (cs)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2154777A1 (en) * 1993-01-27 1994-08-04 Nancy M. Gray Method and composition employing (2r,4s) itraconazole
TW349870B (en) * 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5486625A (en) * 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
ES2112151B1 (es) * 1995-03-17 1999-09-16 Menarini Lab Nuevos compuestos homoquirales para la preparacion de ketoconazol, terconazol y antifungicos relacionados, procedimiento para su fabricacion y utilizacion de los mismos.
EP0954326B2 (en) 1996-04-19 2009-07-22 Grifols Inc. A process for viral inactivation of lyophilized blood proteins
ATE255883T1 (de) * 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
WO1998021205A1 (en) * 1996-11-12 1998-05-22 Sepracor, Inc. 2r,4s,r,r- and 2s,4r,r,r-hydroxyitraconazole
AU5178998A (en) * 1996-11-12 1998-06-03 Sepracor, Inc. 2(r),4(s),(r),(s)- and 2(s),4(r),(r),(s)-hydroxyitraconazole- and hydroxysaperconazole derivatives
AU715999B2 (en) * 1996-11-12 2000-02-17 Sepracor, Inc. Use of cis-hydroxyitraconazole in order to avoid side-effects of itraconazole and hydroxyintraconazole
EP0942907A1 (en) * 1996-11-12 1999-09-22 Sepracor, Inc. 2r, 4s, s, r- and 2s, 4r, s, r-hydroxyitraconazole
CN1102592C (zh) * 1996-11-12 2003-03-05 塞普拉科公司 2r,4s,s,s-和2s,4r,s,s-羟基伊曲康唑
ES2224364T3 (es) 1997-02-11 2005-03-01 Janssen Pharmaceutica N.V. Azoles antifungicos que contienen esteres de aminoacidos.
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
EP0957101A1 (en) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
DK1163234T3 (da) 1999-03-24 2006-02-27 Scherer Technologies Inc R P Farmaceutiske formuleringer med forbedret vandoplöselighed
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003074474A2 (en) 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7078526B2 (en) * 2002-05-31 2006-07-18 Transform Pharmaceuticals, Inc. CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2006500377A (ja) 2002-06-21 2006-01-05 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 改善された溶解性を有する医薬組成物
KR100446256B1 (ko) * 2002-07-11 2004-09-01 경동제약 주식회사 고 광학선택성을 가지는시스-2-(브로모메틸)-2-(2,4-디클로로페닐)-13-디옥소란-4-메틸알콜의 제조방법
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2007017248A2 (en) 2005-08-08 2007-02-15 Abbott Gmbh & Co. Kg Itraconazole compositions with improved bioavailability
JP2009504590A (ja) 2005-08-08 2009-02-05 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつ剤型
EP2404602A1 (en) 2005-08-22 2012-01-11 The Johns Hopkins University Hedgehog pathway antagonists to treat cancer
WO2013036830A1 (en) * 2011-09-09 2013-03-14 The Board Of Trustees Of The Leland Standford Junior University Topical itraconazole formulations and uses thereof
CN102379844A (zh) * 2011-10-31 2012-03-21 广州维美投资有限公司 一种伊曲康唑异构体注射剂
CN105061411A (zh) * 2015-06-23 2015-11-18 扬州艾迪生物科技有限公司 一种光学异构体2s,4r,2’s-伊曲康唑晶型及制备方法与应用
CN106146480B (zh) * 2016-07-18 2019-08-06 山东罗欣药业集团恒欣药业有限公司 一种伊曲康唑的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4287195A (en) * 1978-07-14 1981-09-01 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of [4-(piperazin-1-yl-phenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4490530A (en) * 1981-01-14 1984-12-25 Janssen Pharmaceutica N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1H-imidazoles and 1H-1,2,4-triazoles
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
FR2622198B1 (fr) * 1987-10-21 1992-04-30 Mero Rousselot Satia Compositions granulees de polysaccharides a dissolution aqueuse instantanee, procede pour leur preparation et utilisation
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
HUT58770A (en) * 1989-04-03 1992-03-30 Janssen Pharmaceutica Nv Process for producing regioselective substituted cyclodextrines
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
US5214046A (en) * 1989-07-27 1993-05-25 Hoffmann-La Roche Inc. Substituted aminoalkoxybenzene anti-fungicidal compositions and use
CA2154777A1 (en) * 1993-01-27 1994-08-04 Nancy M. Gray Method and composition employing (2r,4s) itraconazole

Also Published As

Publication number Publication date
RU94045798A (ru) 1996-07-20
HU221189B1 (en) 2002-08-28
WO1993019061A1 (en) 1993-09-30
ES2158859T3 (es) 2001-09-16
RU2127733C1 (ru) 1999-03-20
DE69330248T2 (de) 2002-03-21
FI944311L (fi) 1994-09-16
CZ286619B6 (cs) 2000-05-17
ATE201408T1 (de) 2001-06-15
PL172358B1 (en) 1997-09-30
KR950700904A (ko) 1995-02-20
NO943450D0 (no) 1994-09-16
FI944311A0 (fi) 1994-09-16
HU9402656D0 (en) 1994-11-28
CA2117651A1 (en) 1993-09-30
NZ249494A (en) 1996-04-26
EP0631578A1 (en) 1995-01-04
DK0631578T3 (da) 2001-08-27
DE69330248D1 (de) 2001-06-28
CA2117651C (en) 2006-01-03
CZ221594A3 (en) 1995-01-18
AU665988B2 (en) 1996-01-25
GR3036368T3 (en) 2001-11-30
PT631578E (pt) 2001-11-30
EP0631578B1 (en) 2001-05-23
NO307786B1 (no) 2000-05-29
ZA931906B (en) 1994-09-17
NO943450L (no) 1994-11-11
HK1010729A1 (en) 1999-06-25
AU3632493A (en) 1993-10-21
KR100243534B1 (ko) 2000-03-02
SK110694A3 (en) 1995-04-12
SK283118B6 (sk) 2003-02-04
HUT71835A (en) 1996-02-28
US5998413A (en) 1999-12-07

Similar Documents

Publication Publication Date Title
FI113175B (fi) Menetelmä terapeuttisesti käyttökelpoisten itrakonatsoli- ja saperkonatsoli-cis-stereoisomeerien valmistamiseksi
US6346518B1 (en) Itraconazole and saperconazole stereoisomers
CZ20004108A3 (en) Water soluble azoles exhibiting wide spectrum of antifungal activity
AP1379A (en) 2,4,4-Trisubstituted-1,3-dioxolane antifungals.
HK1010729B (en) Itraconazole and saperconazole stereoisomers
US5236944A (en) Compounds, compositions and anti-neoplastic methods
JP2002543196A (ja) 抗菌・抗カビ性エーテル類
EP0335446A2 (en) Agents for treating neoplasms
JP4473350B2 (ja) 2,4,4−三置換−1,3−ジオキソラン抗菌・抗カビ剤
HK1032404B (en) 2,4,4-trisubstituted-1,3-dioxolane antifungals
MXPA00000453A (en) 2,4,4-trisubstituted-1,3-dioxolane antifungals